185490.KQ EyeGene Inc
- Market cap
- KRW 73.7B
- P/E
- -
- P/B
- 1.47x
- ROE
- -28.7%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 185490.KQ undervalued?
Graham numberThe Graham number of EyeGene Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EyeGene Inc fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-28.7%), below 10%.
ROA 0/1
Return on assets (-23.4%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (19.0%) is above the industry median (1.8%).
Revenue Growth 0/2
Revenue shrank 12.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.3 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.5x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
EyeGene Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/r…
Full company profileEyeGene Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EyeGene Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 267M | 301M | 2.04B | 4.25B | 3.36B | 3.24B | 5.29B | 3.13B | 3.36B | 3.57B | 5.22B |
| Gross Profit | 199M | 97.4M | 762M | 1.94B | 1.55B | 1.50B | 2.75B | 1.89B | 1.16B | 1.12B | 1.36B |
| Operating Income | -8.59B | -9.29B | -8.27B | -9.56B | -14.0B | -36.9B | -23.6B | -27.2B | -13.3B | -9.85B | -15.0B |
| EBITDA | - | - | - | - | - | - | -26.0B | -19.8B | -9.85B | -16.4B | -14.1B |
| Net Income | -8.27B | -8.45B | -5.91B | -8.74B | -14.9B | -34.6B | -26.0B | -21.1B | -12.1B | -15.7B | -14.4B |
| EPS | -629 | -588 | -410 | -581 | -974 | -1,615 | -1,208 | -781 | -449 | -363 | -333 |
| Balance Sheet | |||||||||||
| Total Assets | 18.6B | 30.3B | 54.0B | 47.3B | 44.4B | 105B | 80.4B | 78.1B | 65.3B | 68.1B | 61.4B |
| Total Liabilities | 2.37B | 6.53B | 30.7B | 28.3B | 31.5B | 16.0B | 13.7B | 13.8B | 15.0B | 13.8B | 14.2B |
| Shareholders' Equity | 16.2B | 23.8B | 23.3B | 19.0B | 12.9B | 89.0B | 66.7B | 63.2B | 50.3B | 57.1B | 50.3B |
| Cash & Short-term Investments | 12.9B | 24.5B | 48.9B | 40.6B | 34.2B | 86.2B | 66.5B | 55.4B | 32.5B | 10.2B | 4.14B |
| Total Debt | - | 3.79B | 22.2B | 2.87B | 11.7B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.99B | -6.76B | -7.48B | -8.32B | -9.75B | -30.0B | -18.6B | -20.1B | -12.2B | -5.98B | -12.3B |
| Capital Expenditure | 1.49B | 273M | 243M | 991M | 2.03B | 2.38B | 768M | 1.67B | 4.99B | 1.22B | 76.1M |
| Free Cash Flow | - | - | - | - | -11.8B | -32.8B | -19.5B | -21.8B | -17.2B | -7.20B | -12.3B |
| Ratios | |||||||||||
| ROE | -51.1% | -35.6% | -25.3% | -45.9% | -115.2% | -38.9% | -38.9% | -33.4% | -24.1% | -27.5% | -28.7% |
| ROA | -44.6% | -27.9% | -10.9% | -18.5% | -33.5% | -32.9% | -32.3% | -27.0% | -18.6% | -23.1% | -23.4% |
| Net Profit Margin | -3,094.6% | -2,807.3% | -290.3% | -205.9% | -441.9% | -1,066.2% | -490.3% | -675.3% | -361.4% | -440.3% | -275.8% |
| Debt to Equity | - | 0.16x | 0.95x | 0.15x | 0.90x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EyeGene Inc dividends
EyeGene Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1.2:1 on Jun 28, 2021.
Who owns EyeGene Inc
- Insiders 29.61%
- Institutions 0.00%
- Public & others 70.39%
- Shares outstanding 43.2M
- Free float 30.3M
EyeGene Inc company profile
- Company name
- EyeGene Inc
- Ticker
- 185490.KQ
- ISIN
- KR7185490000
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 47
- Fiscal year end
- December
- Address
- 401 Yangcheon-ro, Seoul, South Korea, 16009
- Phone
- 82 2 322 1687
- Website
- eyegene.co.kr
About EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
EyeGene Inc management
3- Mr. Won-Il YooChief Executive Officer
- Dr. Yang-Je ChoCo-Founder and Chief Technology Officer
- Soobeom LeeChief Financial Officer